A single amino acid substitution in the activation loop defines the decoy characteristic of VEGFR-1/FLT-1

被引:67
作者
Meyer, RD
Mohammadi, M
Rahimi, N
机构
[1] Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02118 USA
[2] Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA
[3] NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA
关键词
D O I
10.1074/jbc.M506454200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
VEGFR-1 is a kinase-defective receptor tyrosine kinase (RTK) and negatively modulates angiogenesis by acting as a decoy receptor. The decoy characteristic of VEGFR-1 is required for normal development and angiogenesis. To date, there is no molecular explanation for this unusual characteristic of VEGFR-1. Here we show that the molecular mechanisms underlying the decoy characteristic of VEGFR-1 is linked to the replacement of a highly conserved amino acid residue in the activation loop. This amino acid is highly conserved among all the type III RTKs and corresponds to aspartic acid, but in VEGFR-1 it is substituted to asparagine. Mutation of asparagine (Asn1050) within the activation loop to aspartic acid promoted enhanced ligand-dependent tyrosine autophosphorylation and kinase activation in vivo and in vitro. The mutant VEGFR-1 (Asp1050) promoted endothelial cell proliferation but not tubulogenesis. It also displayed an oncogenic phenotype as its expression in fibroblast cells elicited transformation and colony growth. Furthermore, mutation of the invariable aspartic acid to asparagine in VEGFR-2 lowered the autophosphorylation of activation loop tyrosines 1052 and 1057. We propose that the conserved aspartic acid in the activation loop favors the transphosphorylation of the activation loop tyrosines, and its absence renders RTK to a less potent enzyme by disfavoring transphosphorylation of activation loop tyrosines.
引用
收藏
页码:867 / 875
页数:9
相关论文
共 50 条
[41]   VEGFR-1 (FLT-1), β1 integrin, and hERG K+ channel for a macromolecular signaling complex in acute myeloid leukemia:: role in cell migration and clinical outcome [J].
Pillozzi, Serena ;
Brizzi, Maria Felice ;
Bernabei, Pietro Antonio ;
Bartolozzi, Benedetta ;
Caporale, Roberto ;
Basile, Venere ;
Boddi, Vied ;
Pegoraro, Luigi ;
Becchetti, Andrea ;
Arcangeli, Annarosa .
BLOOD, 2007, 110 (04) :1238-1250
[43]   Suppression of ovarian cancer by muscle-mediated expression of soluble VEGFR-1/Flt-1 using adeno-associated virus serotype 1-derived vector [J].
Takei, Yuji ;
Mizukami, Hiroaki ;
Saga, Yasushi ;
Yoshimura, Ichiro ;
Hasumi, Yoko ;
Takayama, Takeshi ;
Kohno, Takahiro ;
Matsushita, Takashi ;
Okada, Takashi ;
Kume, Akihiro ;
Suzuki, Mitsuaki ;
Ozawa, Keiya .
INTERNATIONAL JOURNAL OF CANCER, 2007, 120 (02) :278-284
[44]   Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2) - A reassessment using novel receptor-specific vascular endothelial growth factor mutants [J].
Gille, H ;
Kowalski, J ;
Li, B ;
LeCouter, J ;
Moffat, B ;
Zioncheck, TF ;
Pelletier, N ;
Ferrara, N .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (05) :3222-3230
[45]   Absence of mutations in the activation loop and juxtamembrane domains of VEGFR-1 and VEGFR-2 gene in chronic myelomonocytic leukemia (CMML) [J].
Such, Esperanza ;
Cervera, Jose ;
Ibanez, Mariam ;
Gomez-Segui, Ines ;
Luna, Irene ;
Lopez-Pavia, Maria ;
Mallo, Mar ;
Collado, Rosa ;
Vicente, Ana ;
Carlos Hernandez-Boluda, Juan ;
Luno, Elisa ;
Andreu, Rafael ;
Sanz, Guillermo F. ;
Sanz, Miguel A. .
LEUKEMIA RESEARCH, 2012, 36 (03) :E50-E51
[46]   Involvement of VEGFR-2 (kdr/flk-1) but not VEGFR-1 (flt-1) in VEGF-A and VEGF-C-induced tube formation by human microvascular endothelial cells in fibrin matrices in vitro [J].
Koolwijk P. ;
Peters E. ;
Van Der Vecht B. ;
Hornig C. ;
Weich H.A. ;
Alitalo K. ;
Hicklin D.J. ;
Wu Y. ;
Witte L. ;
Van Hinsbergh V.W.M. .
Angiogenesis, 2001, 4 (1) :53-60
[47]   VEGFR-1 (Flt-1) and VEGFR-2 (KDR) stimulate the proliferation of AML cells via the P13-kinase and AKT/protein kinase-B (PKB) signal pathway. [J].
List, AF ;
Glinsmann-Gibson, B ;
Stadheim, C ;
Meuillet, E ;
Bellamy, W ;
Powis, G .
BLOOD, 2000, 96 (11) :301A-301A
[48]   A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases [J].
Meyer, M ;
Clauss, M ;
Lepple-Wienhues, A ;
Waltenberger, J ;
Augustin, HG ;
Ziche, M ;
Lanz, C ;
Büttner, M ;
Rziha, HJ ;
Dehio, C .
EMBO JOURNAL, 1999, 18 (02) :363-374
[49]   Activation of VEGF receptor-1 (VEGFR1, Flt-1) expressed on hematopoietic stem cells promotes cell motility and is essential for marrow reconstitution. [J].
Hattori, K ;
Heissig, B ;
Dias, S ;
Hicklin, DJ ;
Wu, Y ;
Witte, L ;
Zhu, Z ;
Lyden, D ;
Hendrikx, PJ ;
Visser, JWM ;
Crystal, RG ;
Moore, MAS ;
Rafii, S .
BLOOD, 2001, 98 (11) :710A-711A
[50]   Absence of VEGFR-1/Flt-1 signaling pathway in mice results in insensitivity to discogenic low back pain in an established disc injury mouse model (vol 235, pg 5305, 2020) [J].
Qiu, Sujun ;
Shi, Changgui ;
Anbazhagan, Arivarasu Natarajan ;
Das, Vaskar ;
Arora, Vipin ;
Ranjan, K. C. ;
Li, Xin ;
O-Sullivan, InSug ;
van Wijnen, Andre ;
Chintharlapall, Sudhakar ;
Gott-Velis, Gina ;
Richard, Ripper ;
Mwale, Fackson ;
Shibuya, Masabumi ;
Min, Shaoxiong ;
Im, Hee-Jeong .
JOURNAL OF CELLULAR PHYSIOLOGY, 2024, 239 (11)